

# INMODE, LTD. NYSE--INMD

RECENT PRICE **31.19** TRAILING P/E RATIO **15.5** RELATIVE P/E RATIO **1.10** DIV'D YLD **Nil** **VALUE LINE**



© VALUE LINE PUBLISHING LLC	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023/2024
REVENUES PER SH	--	--	--	--	--	2.38	2.73	4.31	--	
"CASH FLOW" PER SH	--	--	--	--	--	.94	1.00	1.99	--	
EARNINGS PER SH	--	--	--	--	--	.80	.89	1.92	<b>NA</b>	<b>NA/NA</b>
DIV'DS DECL'D PER SH	--	--	--	--	--	--	--	--	--	
CAP'L SPENDING PER SH	--	--	--	--	--	.01	.01	.01	--	
BOOK VALUE PER SH	--	--	--	--	--	2.68	3.36	5.01	--	
COMMON SHS OUTST'G (MILL)	--	--	--	--	--	65.60	75.57	82.98	--	
AVG ANN'L P/E RATIO	--	--	--	--	--	20.5	19.3	28.0	<b>NA</b>	<b>NA/NA</b>
RELATIVE P/E RATIO	--	--	--	--	--	1.19	1.13	1.71	--	
AVG ANN'L DIV'D YIELD	--	--	--	--	--	--	--	--	--	
REVENUES (\$MILL)	--	--	--	--	100.2	156.4	206.1	357.6	--	<b>Bold figures are consensus earnings estimates and, using the recent prices, P/E ratios.</b>
OPERATING MARGIN	--	--	--	--	31.6%	38.3%	35.5%	46.8%	--	
DEPRECIATION (\$MILL)	--	--	--	--	.2	.3	.4	.5	--	
NET PROFIT (\$MILL)	--	--	--	--	22.4	61.2	75.0	165.0	--	
INCOME TAX RATE	--	--	--	--	5.3%	1.4%	1.5%	1.7%	--	
NET PROFIT MARGIN	--	--	--	--	22.3%	39.1%	36.4%	46.1%	--	
WORKING CAP'L (\$MILL)	--	--	--	--	48.4	180.7	254.6	418.2	--	
LONG-TERM DEBT (\$MILL)	--	--	--	--	--	--	--	--	--	
SHR. EQUITY (\$MILL)	--	--	--	--	45.5	176.1	254.0	415.8	--	
RETURN ON TOTAL CAP'L	--	--	--	--	49.2%	34.7%	29.5%	39.7%	--	
RETURN ON SHR. EQUITY	--	--	--	--	49.2%	34.7%	29.5%	39.7%	--	
RETAINED TO COM EQ	--	--	--	--	49.2%	34.7%	29.5%	39.7%	--	
ALL DIV'DS TO NET PROF	--	--	--	--	--	--	--	--	--	

Note: No analyst estimates available.

ANNUAL RATES						ASSETS (\$mill.)						INDUSTRY: Med Supp Non-Invasive																			
of change (per share)		5 Yrs.	1 Yr.	2019		2020		12/31/21		<b>BUSINESS:</b> InMode, Ltd. manufactures and commercializes innovative minimally and non-invasive aesthetic medical products. The company has developed products that apply its technology to rejuvenate the skin's appearance through body and face reshaping and tightening, the treatment of superficial benign vascular and pigmented lesions, hair removal, wrinkle reduction and the treatment of acne, cellulite and leg veins. InMode expanded its product offerings to include eight product platforms: BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, Evolve and Evoke. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. Its international sales accounted for approximately 34% of InMode total revenue for the year ended December 31, 2021. Has 362 employees. Chairman & C.E.O.: Moshe Mizrahy Address: Tavor Building, Sha'ar Yokneam P.O. Box 533, Yokneam IL. Tel.: (4) 9096313. Internet: www.inmodemd.com. <i>L. Y.</i>																					
Sales	--	58.0%	58.0%	193.4	260.5	10.4	11.6	22.1	21.0							<p><b>September 16, 2022</b></p> <p><b>TOTAL SHAREHOLDER RETURN</b> <i>Dividends plus appreciation as of 8/31/2022</i></p> <table border="1"> <thead> <tr> <th>3 Mos.</th> <th>6 Mos.</th> <th>1 Yr.</th> <th>3 Yrs.</th> <th>5 Yrs.</th> </tr> </thead> <tbody> <tr> <td>19.13%</td> <td>-25.18%</td> <td>-51.19%</td> <td>221.01%</td> <td>--</td> </tr> </tbody> </table>						3 Mos.	6 Mos.	1 Yr.	3 Yrs.	5 Yrs.	19.13%	-25.18%	-51.19%	221.01%	--
3 Mos.	6 Mos.	1 Yr.	3 Yrs.	5 Yrs.																											
19.13%	-25.18%	-51.19%	221.01%	--																											
"Cash Flow"	--	100.0%	100.0%	9.4	15.0	.9	1.0	1.4	7.0																						
Earnings	--	115.5%	115.5%	.0	2.5	28.8	28.6	43.1	51.9																						
Dividends	--	--	--	218.4	295.8	3.7	6.4	8.8	8.8																						
Book Value	--	49.0%	49.0%	2.2	2.6	.0	.0	.0	.0																						
				Property, Plant & Equip, at cost		2.2		2.6														3.6									
				Accum Depreciation		1.3		1.6														2.2									
				Net Property		.9		1.0		1.4																					
				Other		4.3		5.2		7.0																					
				Total Assets		218.4		295.8		478.5																					
				LIABILITIES (\$mill.)		3.7		6.4		8.8																					
				Accts Payable		.0		.0		.0																					
				Debt Due		.0		.0		.0																					
				Other		28.8		28.6		43.1																					
				Current Liab		32.5		35.0		51.9																					
				LONG-TERM DEBT AND EQUITY as of 12/31/21		None		None		None																					
				Total Debt None		Due in 5 Yrs. None		None		None																					
				LT Debt None		None		None		None																					
				Including Cap. Leases		None		None		None																					
				Leases, Uncapitalized		Annual rentals \$1.3 mill.		None		None																					
				Pension Liability		None in '21 vs. None in '20		None		None																					
				Pfd Stock		None		Pfd Div'd Paid		None																					
				Common Stock		82,978,115 shares		(100% of Cap'l)		None																					
				INSTITUTIONAL DECISIONS		4Q'21		1Q'22		2Q'22																					
to Buy		319		196		139																									
to Sell		86		178		194																									
Hld's(000)		44017		48387		45732																									

© 2022 Value Line, Inc. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.

To subscribe call 1-800-VALUELINE